Cidara Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 93 out of 399 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 215.88.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Cidara Therapeutics Inc is 6.75, ranking 224 out of 399 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Key Metrics
The current valuation score of Cidara Therapeutics Inc is 6.29, ranking 306 out of 399 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.74, which is -100.00% below the recent high of 0.00 and 0.00% above the recent low of -19.74.
The current earnings forecast score of Cidara Therapeutics Inc is 6.75, ranking 332 out of 399 in the Biotechnology & Medical Research industry. The average price target is 221.50, with a high of 221.50 and a low of 199.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Cidara Therapeutics Inc is 6.52, ranking 225 out of 399 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 222.00 and the support level at 220.18, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The latest institutional shareholding proportion is 93.43%, representing a quarter-over-quarter decrease of 17.37%. The largest institutional shareholder is Steven Cohen, holding a total of 1.58M shares, representing 5.02% of shares outstanding, with 382.81% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cidara Therapeutics Inc is 5.20, ranking 55 out of 399 in the Biotechnology & Medical Research industry. The company's beta value is 1.57. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
